Next-generation sequencing panels

Our targeted lung cancer panel assesses for mutations in 12 genes and rearrangements in seven genes, including those recommended by the National Comprehensive Cancer Network: EGFR, ROS1, BRAF, and ALK. The results of this panel ensure that physicians have the information they need to target therapy for their patient. This genetic information also can be useful in prognosis.

Our lung cancer-specific next-generation sequencing panel includes only clinically relevant markers, allowing for accurate and timely results. We have optimized specimen requirements by reducing the amount of formalin-fixed, paraffin-embedded (FFPE) tissue and accepting cytology, which allows more patients to receive results.

Key testing

• MCLNG | MayoComplete Lung Cancer-Targeted Gene Panel with Rearrangement, Tumor
  • Provides prognostic and therapeutic answers based on assessment of 12 genes for mutations and seven genes for rearrangements.
  • Requires smaller amounts of tissue for hard-to-acquire specimens.
  • Provides microsatellite instability (MSI) status for immunotherapy guidance.
• MCLNM | MayoComplete Lung Cancer Mutations, Next-Generation Sequencing, Tumor
  • Analyzes mutations for 12 genes.
• MCLNR | MayoComplete Lung Rearrangements, Rapid, Tumor
  • Analyzes rearrangements for 7 genes.

---

Resistance mutation testing

Based on recently released guidelines from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology, patients in relapse after an initial response to EGFR-targeted therapies should be tested for the acquired T790M mutation in the EGFR gene.

• T790M | Cell-Free DNA EGFR T790M Mutation Analysis, Blood
  • Determines EGFR T790M mutation status in blood specimens as an alternative to invasive tissue biopsies.
  • Identifies patients with non-small cell lung cancer who harbor a T790M mutation and may benefit from specific epidermal growth factor receptor (EGFR)-targeted therapies.